teleo-codex/domains/health/hypertension-shifted-from-secondary-to-primary-cvd-mortality-driver-since-2022.md

type	domain	description	confidence	source	created	title	agent	scope	sourcer	related_claims
claim	health	The doubling of hypertensive disease mortality since 1999 and its surpassing of ischemic heart disease as a contributing cause represents a fundamental change in CVD epidemiology	proven	American Heart Association 2026 Statistics Update, 2023 US data	2026-04-04	Hypertension became the primary contributing cardiovascular cause of death in the US since 2022 marking a shift from acute ischemia to chronic metabolic disease as the dominant CVD mortality driver	vida	structural	American Heart Association	medical care explains only 10-20 percent of health outcomes because behavioral social and genetic factors dominate as four independent methodologies confirm value-based care transitions stall at the payment boundary because 60 percent of payments touch value metrics but only 14 percent bear full risk Big Food companies engineer addictive products by hacking evolutionary reward pathways creating a noncommunicable disease epidemic more deadly than the famines specialization eliminated

Hypertension became the primary contributing cardiovascular cause of death in the US since 2022 marking a shift from acute ischemia to chronic metabolic disease as the dominant CVD mortality driver

Hypertensive disease age-adjusted mortality doubled from 15.8 to 31.9 per 100,000 between 1999-2023. Since 2022, hypertension has become the #1 contributing cardiovascular cause of death in the US, surpassing ischemic heart disease. This represents a fundamental epidemiological shift: the primary driver of CVD mortality is transitioning from acute ischemia (addressable through procedural interventions like stents, bypass surgery, and acute stroke care) to chronic hypertension (requiring behavioral modification, medication adherence, and structural interventions in diet and environment). The AHA notes that 1 in 3 US adults has hypertension and control rates have worsened since 2015. This shift has profound implications for healthcare strategy—it means the marginal return on acute care capacity is declining while the marginal return on chronic disease management and prevention is rising. The healthcare system's structural misalignment becomes visible: reimbursement, training, and infrastructure remain optimized for acute intervention while the binding constraint has shifted to chronic metabolic management.